CA2478801A1 — Method for administration of growth hormone via pulmonary delivery
Assigned to Eli Lilly and Co · Expires 2003-10-02 · 23y expired
What this patent protects
The claimed invention relates to a method of treating a human patient with growth hormone deficiency or a non-growth hormone deficiency disorder treatable with hGH, which comprises administering human growth hormone to the deep lung to said patient by a pulmonary device.
USPTO Abstract
The claimed invention relates to a method of treating a human patient with growth hormone deficiency or a non-growth hormone deficiency disorder treatable with hGH, which comprises administering human growth hormone to the deep lung to said patient by a pulmonary device.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.